Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer
Status:
Completed
Trial end date:
2020-02-15
Target enrollment:
Participant gender:
Summary
This was a Phase 1, multicenter, open-label, clinical trial in adult subjects with metastatic
castrate resistant prostate cancer who progressed after both hormonal therapy (abiraterone or
enzalutamide) and chemotherapy (docetaxel), or cannot tolerate either or both therapies.
The study involved a Phase 1 dose escalation of oral GT0918 to evaluate its safety,
tolerability, pharmacokinetics and pharmacodynamics.